- Is it possible to predict the development of an entecavir resistance mutation in patients with chronic hepatitis B in clinical practice?
-
Nam JY, Lee JH
- KMID: 2406038
- Clin Mol Hepatol.
- 2017 Dec;23(4):311-313.
- doi: 10.3350/cmh.2017.0069
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Lamivudine: fading into the mists of time
-
Choi J, Lim YS
- KMID: 2406039
- Clin Mol Hepatol.
- 2017 Dec;23(4):314-315.
- doi: 10.3350/cmh.2017.0110
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Use of sofosbuvir in chronic kidney disease: Is it necessary?
-
Lim TS, Ahn SH
- KMID: 2406037
- Clin Mol Hepatol.
- 2017 Dec;23(4):308-310.
- doi: 10.3350/cmh.2017.0109
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Histopathological evaluation of liver fibrosis and cirrhosis regression
-
Lo RC, Kim H
- KMID: 2406036
- Clin Mol Hepatol.
- 2017 Dec;23(4):302-307.
- doi: 10.3350/cmh.2017.0078
The hepatic repair complex in the setting of cirrhosis has received increasing attention, as it implies the regression of cirrhosis, which was traditionally taken to be an irreversible state. In... -
- CITED
-
- Close
- SHARE
-
- Close
- Treatment options after sorafenib failure in patients with hepatocellular carcinoma
-
Dika IE, Abou-Alfa
- KMID: 2406033
- Clin Mol Hepatol.
- 2017 Dec;23(4):273-279.
- doi: 10.3350/cmh.2017.0108
Second line therapy after failure of sorafenib continues to be under study. Prognosis of hepatocellular carcinoma is measured in months, with median overall survival reaching 10.7 months with sorafenib. Because... -
- CITED
-
- Close
- SHARE
-
- Close
- Recent advances in transarterial embolotherapies in the treatment of hepatocellular carcinoma
-
Lee EW, Khan S
- KMID: 2406032
- Clin Mol Hepatol.
- 2017 Dec;23(4):265-272.
- doi: 10.3350/cmh.2017.0111
Management of hepatocellular carcinoma (HCC) can be maximized with the utilization of multiple treatment modalities including transplant, surgical resection and locoregional therapies including ablative therapies and transarterial embolotherapies. Although transplant... -
- CITED
-
- Close
- SHARE
-
- Close
- Imaging evaluation of non-alcoholic fatty liver disease: focused on quantification
-
Lee DH
- KMID: 2406035
- Clin Mol Hepatol.
- 2017 Dec;23(4):290-301.
- doi: 10.3350/cmh.2017.0042
Non-alcoholic fatty liver disease (NAFLD) has been an emerging major health problem, and the most common cause of chronic liver disease in Western countries. Traditionally, liver biopsy has been gold... -
- CITED
-
- Close
- SHARE
-
- Close
- Contrast-enhanced ultrasound (CEUS) liver imaging reporting and data system (LI-RADS) 2017 – a review of important differences compared to the CT/MRI system
-
Kim TK, Noh SY, Wilson SR, Kono Y, Piscaglia , Jang HJ, Lyshchik A, Dietrich C, Willmann J, Vezeridis , Sirlin CB
- KMID: 2406034
- Clin Mol Hepatol.
- 2017 Dec;23(4):280-289.
- doi: 10.3350/cmh.2017.0037
Medical imaging plays an important role in the diagnosis and management of hepatocellular carcinoma (HCC). The Liver Imaging Reporting and Data System (LI-RADS) was initially created to standardize the reporting... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy and safety of sofosbuvir-based regimens for treatment in chronic hepatitis C genotype 1 patients with moderately impaired renal function
-
Shin HP, Park JA, Burman B, Kozarek RA, Siddique A
- KMID: 2406040
- Clin Mol Hepatol.
- 2017 Dec;23(4):316-322.
- doi: 10.3350/cmh.2016.0087
BACKGROUND/AIMS: Treatment of chronic hepatitis C virus (HCV) infection in patients with chronic kidney disease (CKD) is essential. The availability of sofosbuvir (SOF) has dramatically improved overall HCV cure rates,... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical characteristics of patients with chronic hepatitis B who developed genotypic resistance to entecavir: Real-life experience
-
Kim HJ, Cho YK, Jeon WK, Kim BI
- KMID: 2406041
- Clin Mol Hepatol.
- 2017 Dec;23(4):323-330.
- doi: 10.3350/cmh.2017.0005
BACKGROUND/AIMS: Clinical characteristics of patients with chronic hepatitis B (CHB) who developed genotypic resistance to entecavir (ETV) were compared to those without resistance. METHODS: Two hundred fifty eight CHB patients who... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy and safety of entecavir versus lamivudine over 5 years of treatment: A randomized controlled trial in Korean patients with hepatitis B e antigen-negative chronic hepatitis B
-
Lee KS, Kweon YO, Um SH, Kim BH, Lim YS, Paik SW, Heo J, Lee HJ, Kim DJ, Kim TH, Lee YS, Byun KS, Kim D, Lee MS, Yu K, Suh DJ
- KMID: 2406042
- Clin Mol Hepatol.
- 2017 Dec;23(4):331-339.
- doi: 10.3350/cmh.2016.0040
BACKGROUND/AIMS: Long-term data on antiviral therapy in Korean patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB) are limited. This study evaluated the efficacy and safety of entecavir... -
- CITED
-
- Close
- SHARE
-
- Close
- Complete response of advanced hepatocellular carcinoma to sorafenib: another case and a comprehensive review
-
Kim TS, Kim JH, Kim BH, Lee YS, Yoo YJ, Kang SH, Suh SJ, Jung YK, Seo YS, Yim HJ, Yeon JE, Byun KS
- KMID: 2406043
- Clin Mol Hepatol.
- 2017 Dec;23(4):340-346.
- doi: 10.3350/cmh.2016.0070
Since sorafenib was introduced in 2007 for treating advanced hepatocellular carcinoma (HCC), 15 patients have achieved a complete response (CR) in advanced HCC. However, only four of these reports can... -
- CITED
-
- Close
- SHARE
-
- Close
